SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Allscripts Healthcare Solutions, Inc. – ‘10-Q’ for 6/30/22 – ‘EX-31.2’

On:  Monday, 8/8/22, at 4:01pm ET   ·   For:  6/30/22   ·   Accession #:  950170-22-15497   ·   File #:  1-35547

Previous ‘10-Q’:  ‘10-Q’ on 5/9/22 for 3/31/22   ·   Next & Latest:  ‘10-Q’ on 11/7/22 for 9/30/22   ·   1 Reference:  To:  Veradigm Inc. – ‘8-K’ on 5/5/22 for 5/2/22

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/08/22  Allscripts Healthcare Soluti… Inc 10-Q        6/30/22  104:19M                                    Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   5.02M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     32K 
10: R1          Document and Entity Information                     HTML     84K 
11: R2          Consolidated Balance Sheets (Unaudited)             HTML    167K 
12: R3          Consolidated Balance Sheets (Unaudited)             HTML     57K 
                (Parenthetical)                                                  
13: R4          Consolidated Statements of Operations (Unaudited)   HTML    160K 
14: R5          Consolidated Statements of Comprehensive Income     HTML     66K 
                (Loss) (Unaudited)                                               
15: R6          Consolidated Statements of Stockholders' Equity     HTML    158K 
                (Unaudited)                                                      
16: R7          Consolidated Statements of Stockholders Equity      HTML     31K 
                (Parenthetical)                                                  
17: R8          Consolidated Statements of Cash Flows (Unaudited)   HTML    150K 
18: R9          Basis of Presentation and Significant Accounting    HTML     45K 
                Policies                                                         
19: R10         Revenue from Contracts with Customers               HTML    215K 
20: R11         Accounts Receivable                                 HTML     54K 
21: R12         Leases                                              HTML    136K 
22: R13         Business Combinations and Divestitures              HTML     89K 
23: R14         Fair Value Measurements and Long-term Investments   HTML    187K 
24: R15         Stockholders' Equity                                HTML    155K 
25: R16         Earnings (Loss) Per Share                           HTML    233K 
26: R17         Goodwill and Intangible Assets                      HTML    162K 
27: R18         Debt                                                HTML    210K 
28: R19         Income Taxes                                        HTML     76K 
29: R20         Derivative Financial Instruments                    HTML    157K 
30: R21         Accumulated Other Comprehensive Loss                HTML    280K 
31: R22         Contingencies                                       HTML     41K 
32: R23         Discontinued Operations                             HTML    357K 
33: R24         Business Segments                                   HTML    142K 
34: R25         Supplemental Disclosures                            HTML     66K 
35: R26         Basis of Presentation and Significant Accounting    HTML     69K 
                Policies (Policies)                                              
36: R27         Revenue from Contracts with Customers (Tables)      HTML    202K 
37: R28         Accounts Receivable (Tables)                        HTML     54K 
38: R29         Leases (Tables)                                     HTML    135K 
39: R30         Business Combinations and Divestitures (Tables)     HTML     76K 
40: R31         Fair Value Measurements and Long-term Investments   HTML    181K 
                (Tables)                                                         
41: R32         Stockholders' Equity (Tables)                       HTML    139K 
42: R33         Earnings (Loss) Per Share (Tables)                  HTML    233K 
43: R34         Goodwill and Intangible Assets (Tables)             HTML    165K 
44: R35         Debt (Tables)                                       HTML    159K 
45: R36         Income Taxes (Tables)                               HTML     63K 
46: R37         Derivative Financial Instruments (Tables)           HTML    153K 
47: R38         Accumulated Other Comprehensive Loss (Tables)       HTML    280K 
48: R39         Discontinued Operations (Tables)                    HTML    356K 
49: R40         Business Segments (Tables)                          HTML    133K 
50: R41         Supplemental Disclosures (Tables)                   HTML     65K 
51: R42         Basis of Presentation and Significant Accounting    HTML     69K 
                Policies - Additional Information (Detail)                       
52: R43         Revenue from Contracts with Customers - Additional  HTML     45K 
                Information (Detail)                                             
53: R44         Revenue from Contracts with Customers - Summary of  HTML     44K 
                Revenue Recognized on Various Performance                        
                Obligations and Elected Accounting Expedients                    
                (Detail)                                                         
54: R45         Revenue from Contracts with Customers - Summary of  HTML     54K 
                Revenue by Type and Nature of Revenue Stream by                  
                Reportable Segments (Detail)                                     
55: R46         Revenue from Contracts with Customers - Summary of  HTML     40K 
                Changes in Estimate of Credit Losses for Contract                
                Assets (Details)                                                 
56: R47         Accounts Receivable - Schedule of Changes in        HTML     38K 
                Estimate of Credit Losses for Trade Accounts                     
                Receivable (Detail)                                              
57: R48         Leases - Additional Information (Detail)            HTML     37K 
58: R49         Leases - Summary of Operating Costs Associated      HTML     37K 
                with Leased Assets (Detail)                                      
59: R50         Leases - Supplemental Cash Flow Information for     HTML     34K 
                Operating Leases (Detail)                                        
60: R51         Leases - Summary of Balance Sheet Location and      HTML     40K 
                Balances for Operating Leases (Detail)                           
61: R52         Leases - Summary of Future Maturities of Lease and  HTML     51K 
                Non-Lease Components (Detail)                                    
62: R53         Business Combinations and Divestitures -            HTML     91K 
                Additional Information (Detail)                                  
63: R54         Business Combinations and Divestitures - Schedule   HTML     53K 
                of Assets Acquired and Liabilities Assumed                       
                (Detail)                                                         
64: R55         Business Combinations and Divestitures - Schedule   HTML     42K 
                of Acquired Intangible Assets Amortization                       
                (Detail)                                                         
65: R56         Fair Value Measurements and Long-term Investments   HTML     59K 
                - Summary of Financial Assets and Liabilities                    
                Measured at Fair Value on Recurring Basis (Detail)               
66: R57         Fair Value Measurements and Long-term Investments   HTML     37K 
                - Summary of Changes in Liability Measured at Fair               
                Value on Recurring Basis (Detail)                                
67: R58         Fair Value Measurements and Long-term Investments   HTML     48K 
                - Summary of Long-term Equity Investments Included               
                in Other Assets (Detail)                                         
68: R59         Fair Value Measurements and Long-term Investments   HTML     41K 
                - Additional Information (Detail)                                
69: R60         Stockholders' Equity - Additional Information       HTML     66K 
                (Detail)                                                         
70: R61         Stockholders' Equity - Stock-Based Compensation     HTML     44K 
                Expense (Detail)                                                 
71: R62         Stockholders' Equity - Stock-Based Awards Granted   HTML     43K 
                (Detail)                                                         
72: R63         Earnings (Loss) Per Share - Calculations of         HTML     98K 
                Earnings (Loss) Per Share (Detail)                               
73: R64         Earnings (Loss) Per Share - Anti-Dilutive Stock     HTML     32K 
                Options, Restricted Stock Unit Awards and Warrants               
                Excluded from Computation of Diluted Earnings                    
                (Loss) Per Share (Detail)                                        
74: R65         Goodwill and Intangible Assets - Goodwill and       HTML     50K 
                Intangible Assets (Detail)                                       
75: R66         Goodwill and Intangible Assets - Changes in         HTML     42K 
                Carrying Amount of Goodwill (Detail)                             
76: R67         Goodwill and Intangible Assets - Additional         HTML     32K 
                Information (Detail)                                             
77: R68         Debt - Debt Outstanding Excluding Lease             HTML     43K 
                Obligations (Detail)                                             
78: R69         Debt - Debt Outstanding Excluding Lease             HTML     43K 
                Obligations (Parenthetical) (Detail)                             
79: R70         Debt - Interest Expense (Detail)                    HTML     41K 
80: R71         Debt - Interest Expense Related to 0.875%           HTML     40K 
                Convertible Senior Notes (Detail)                                
81: R72         Debt - Additional Information (Detail)              HTML    100K 
82: R73         Debt - Summary of Future Debt Payment Obligations   HTML     54K 
                (Detail)                                                         
83: R74         Debt - Summary of Future Debt Payment Obligations   HTML     33K 
                (Parenthetical) (Detail)                                         
84: R75         Income Taxes - Effective Tax Rates (Detail)         HTML     41K 
85: R76         Income Taxes - Additional Information (Detail)      HTML     45K 
86: R77         Derivative Financial Instruments - Fair Value and   HTML     43K 
                Balance Sheet Locations (Detail)                                 
87: R78         Derivative Financial Instruments - Additional       HTML     45K 
                Information (Detail)                                             
88: R79         Derivative Financial Instruments - Derivatives      HTML     45K 
                Instruments Designated as Cash Flow Hedges                       
                (Detail)                                                         
89: R80         Accumulated Other Comprehensive Loss - Components   HTML     66K 
                of Accumulated Other Comprehensive Loss (Detail)                 
90: R81         Accumulated Other Comprehensive Loss - Components   HTML     33K 
                of Accumulated Other Comprehensive Loss                          
                (Parenthetical) (Detail)                                         
91: R82         Accumulated Other Comprehensive Loss - Income Tax   HTML     79K 
                Effects Related to Components of Other                           
                Comprehensive Income (Loss) (Detail)                             
92: R83         Contingencies - Additional Information (Detail)     HTML     47K 
93: R84         Discontinued Operations - Additional Information    HTML     36K 
                (Detail)                                                         
94: R85         Discontinued Operations - Summary of Major Classes  HTML    117K 
                of Assets and Liabilities as Reported on                         
                Consolidated Balance Sheets (Detail)                             
95: R86         Discontinued Operations - Summary of Major Classes  HTML     37K 
                of Assets and Liabilities as Reported on                         
                Consolidated Balance Sheets (Parenthetical)                      
                (Detail)                                                         
96: R87         Discontinued Operations - Summary of Major Income   HTML     90K 
                and Expense Line Items Reported in Consolidated                  
                Statements of Operations (Detail)                                
97: R88         Business Segments - Additional Information          HTML     35K 
                (Detail)                                                         
98: R89         Business Segments - Revenues and Income (Loss)      HTML     53K 
                from Operations Related to Segment Within                        
                Reconciliation to Consolidated Amounts (Detail)                  
99: R90         Supplemental Disclosures - Supplemental             HTML     43K 
                Disclosures (Detail)                                             
102: XML         IDEA XML File -- Filing Summary                      XML    201K  
100: XML         XBRL Instance -- mdrx-20220630_htm                   XML   5.50M  
101: EXCEL       IDEA Workbook of Financial Reports                  XLSX    190K  
 7: EX-101.CAL  XBRL Calculations -- mdrx-20220630_cal               XML    281K 
 5: EX-101.DEF  XBRL Definitions -- mdrx-20220630_def                XML   1.01M 
 8: EX-101.LAB  XBRL Labels -- mdrx-20220630_lab                     XML   1.83M 
 9: EX-101.PRE  XBRL Presentations -- mdrx-20220630_pre              XML   1.45M 
 6: EX-101.SCH  XBRL Schema -- mdrx-20220630                         XSD    257K 
103: JSON        XBRL Instance as JSON Data -- MetaLinks              569±   936K  
104: ZIP         XBRL Zipped Folder -- 0000950170-22-015497-xbrl      Zip    473K

‘EX-31.2’   —   Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

  EX-31.2  

Exhibit 31.2

Certification

I, Leah S. Jones, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Allscripts Healthcare Solutions, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: August 8, 2022

 

/s/ Leah S. Jones

 

 

Chief Financial Officer

 

Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:8/8/22None on these Dates
For Period end:6/30/22
 List all Filings 

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/05/22  Veradigm Inc.                     8-K:2,5,9   5/02/22   13:2.1M                                   Donnelley … Solutions/FA
↑Top
Filing Submission 0000950170-22-015497   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., Apr. 27, 8:00:10.1am ET